Evoke Pharma Debt to Equity Ratio 2012-2024 | EVOK
Current and historical debt to equity ratio values for Evoke Pharma (EVOK) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Evoke Pharma debt/equity for the three months ending September 30, 2024 was 0.00.
Evoke Pharma Debt/Equity Ratio Historical Data |
Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
2024-09-30 |
$0.01B |
$0.00B |
2.23 |
2024-06-30 |
$0.01B |
$0.00B |
3.55 |
2024-03-31 |
$0.01B |
$0.00B |
2.56 |
2023-12-31 |
$0.01B |
$-0.00B |
-3.74 |
2023-09-30 |
$0.01B |
$-0.00B |
-9.99 |
2023-06-30 |
$0.01B |
$0.00B |
15.68 |
2023-03-31 |
$0.01B |
$0.00B |
3.72 |
2022-12-31 |
$0.01B |
$0.00B |
1.90 |
2022-09-30 |
$0.01B |
$0.01B |
1.42 |
2022-06-30 |
$0.01B |
$0.01B |
1.00 |
2022-03-31 |
$0.01B |
$0.00B |
3.67 |
2021-12-31 |
$0.01B |
$0.00B |
1.97 |
2021-09-30 |
$0.01B |
$0.01B |
1.44 |
2021-06-30 |
$0.01B |
$0.01B |
1.94 |
2021-03-31 |
$0.01B |
$0.01B |
1.47 |
2020-12-31 |
$0.01B |
$-0.00B |
-3.94 |
2020-09-30 |
$0.01B |
$-0.00B |
-4.51 |
2020-06-30 |
$0.01B |
$0.00B |
-23.12 |
2020-03-31 |
$0.00B |
$0.00B |
0.59 |
2019-12-31 |
$0.00B |
$0.00B |
0.46 |
2019-09-30 |
$0.00B |
$0.01B |
0.42 |
2019-06-30 |
$0.00B |
$0.01B |
0.20 |
2019-03-31 |
$0.00B |
$0.00B |
0.42 |
2018-12-31 |
$0.00B |
$0.00B |
0.41 |
2018-09-30 |
$0.00B |
$0.01B |
0.30 |
2018-06-30 |
$0.00B |
$0.01B |
0.24 |
2018-03-31 |
$0.00B |
$0.00B |
0.27 |
2017-12-31 |
$0.01B |
$0.00B |
2.67 |
2017-09-30 |
$0.01B |
$0.00B |
4.22 |
2017-06-30 |
$0.01B |
$0.01B |
0.94 |
2017-03-31 |
$0.01B |
$0.01B |
0.87 |
2016-12-31 |
$0.01B |
$0.00B |
1.45 |
2016-09-30 |
$0.01B |
$0.01B |
1.30 |
2016-06-30 |
$0.01B |
$-0.00B |
-4.04 |
2016-03-31 |
$0.01B |
$0.00B |
8.08 |
2015-12-31 |
$0.01B |
$0.00B |
1.75 |
2015-09-30 |
$0.01B |
$0.01B |
1.20 |
2015-06-30 |
$0.01B |
$0.00B |
1.46 |
2015-03-31 |
$0.01B |
$0.01B |
0.96 |
2014-12-31 |
$0.01B |
$0.01B |
0.66 |
2014-09-30 |
$0.00B |
$0.01B |
0.15 |
2014-06-30 |
$0.00B |
$0.02B |
0.12 |
2014-03-31 |
$0.00B |
$0.02B |
0.22 |
2013-12-31 |
$0.00B |
$0.02B |
0.18 |
2013-09-30 |
$0.01B |
$0.02B |
0.24 |
2013-06-30 |
$0.00B |
$-0.00B |
-1.83 |
2013-03-31 |
$0.00B |
$0.00B |
0.00 |
2012-12-31 |
$0.00B |
|
0.00 |
2012-09-30 |
$0.00B |
$0.00B |
0.00 |
2012-06-30 |
$0.00B |
$0.00B |
0.00 |
2011-12-31 |
$0.00B |
$0.00B |
0.58 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.007B |
$0.005B |
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|